SCPHARMACEUTICALS INC (SCPH) Fundamental Analysis & Valuation

NASDAQ:SCPH • US8106481059

Current stock price

5.67 USD
0 (0%)
At close:
5.77 USD
+0.1 (+1.76%)
After Hours:

This SCPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SCPH Profitability Analysis

1.1 Basic Checks

  • In the past year SCPH has reported negative net income.
  • In the past year SCPH has reported a negative cash flow from operations.
  • SCPH had negative earnings in each of the past 5 years.
  • In the past 5 years SCPH always reported negative operating cash flow.
SCPH Yearly Net Income VS EBIT VS OCF VS FCFSCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • With a Return On Assets value of -114.28%, SCPH is not doing good in the industry: 79.49% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -114.28%
ROE N/A
ROIC N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
SCPH Yearly ROA, ROE, ROICSCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • Looking at the Gross Margin, with a value of 68.46%, SCPH is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
  • SCPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPH Yearly Profit, Operating, Gross MarginsSCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SCPH Health Analysis

2.1 Basic Checks

  • SCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SCPH has been increased compared to 1 year ago.
  • Compared to 5 years ago, SCPH has more shares outstanding
  • SCPH has a worse debt/assets ratio than last year.
SCPH Yearly Shares OutstandingSCPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SCPH Yearly Total Debt VS Total AssetsSCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • SCPH has an Altman-Z score of -6.50. This is a bad value and indicates that SCPH is not financially healthy and even has some risk of bankruptcy.
  • SCPH's Altman-Z score of -6.50 is on the low side compared to the rest of the industry. SCPH is outperformed by 63.08% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.5
ROIC/WACCN/A
WACC9.31%
SCPH Yearly LT Debt VS Equity VS FCFSCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • SCPH has a Current Ratio of 3.85. This indicates that SCPH is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.85, SCPH is in the better half of the industry, outperforming 62.56% of the companies in the same industry.
  • SCPH has a Quick Ratio of 3.14. This indicates that SCPH is financially healthy and has no problem in meeting its short term obligations.
  • SCPH has a Quick ratio of 3.14. This is comparable to the rest of the industry: SCPH outperforms 59.49% of its industry peers.
Industry RankSector Rank
Current Ratio 3.85
Quick Ratio 3.14
SCPH Yearly Current Assets VS Current LiabilitesSCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SCPH Growth Analysis

3.1 Past

  • SCPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.03%.
  • SCPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 107.75%.
EPS 1Y (TTM)-16.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
Revenue 1Y (TTM)107.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%99.17%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.37% on average over the next years. This is a very strong growth
  • SCPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.16% yearly.
EPS Next Y41.66%
EPS Next 2Y38.35%
EPS Next 3Y33.08%
EPS Next 5Y24.37%
Revenue Next Year100.79%
Revenue Next 2Y88.02%
Revenue Next 3Y72.57%
Revenue Next 5Y52.16%

3.3 Evolution

SCPH Yearly Revenue VS EstimatesSCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SCPH Yearly EPS VS EstimatesSCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. SCPH Valuation Analysis

4.1 Price/Earnings Ratio

  • SCPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPH Price Earnings VS Forward Price EarningsSCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPH Per share dataSCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SCPH's earnings are expected to grow with 33.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.35%
EPS Next 3Y33.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SCPH Dividend Analysis

5.1 Amount

  • SCPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SCPH Fundamentals: All Metrics, Ratios and Statistics

SCPHARMACEUTICALS INC

NASDAQ:SCPH (10/6/2025, 9:01:22 PM)

After market: 5.77 +0.1 (+1.76%)

5.67

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07
Earnings (Next)11-05
Inst Owners62.64%
Inst Owner Change-94.49%
Ins Owners5.98%
Ins Owner Change-20.97%
Market Cap304.37M
Revenue(TTM)49.97M
Net Income(TTM)-91.72M
Analysts76
Price Target12.33 (117.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.79%
Min EPS beat(2)-21.73%
Max EPS beat(2)-11.86%
EPS beat(4)1
Avg EPS beat(4)-43.07%
Min EPS beat(4)-147.99%
Max EPS beat(4)9.3%
EPS beat(8)3
Avg EPS beat(8)-18.67%
EPS beat(12)7
Avg EPS beat(12)-7.96%
EPS beat(16)10
Avg EPS beat(16)-3.09%
Revenue beat(2)1
Avg Revenue beat(2)0.56%
Min Revenue beat(2)-0.92%
Max Revenue beat(2)2.03%
Revenue beat(4)1
Avg Revenue beat(4)-2.33%
Min Revenue beat(4)-9%
Max Revenue beat(4)2.03%
Revenue beat(8)4
Avg Revenue beat(8)0.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.49%
EPS NY rev (1m)-1.8%
EPS NY rev (3m)-3.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.09
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.93
BVpS-0.4
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.46%
FCFM N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.85
Quick Ratio 3.14
Altman-Z -6.5
F-Score2
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)23.53%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
EPS Next Y41.66%
EPS Next 2Y38.35%
EPS Next 3Y33.08%
EPS Next 5Y24.37%
Revenue 1Y (TTM)107.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%99.17%
Revenue Next Year100.79%
Revenue Next 2Y88.02%
Revenue Next 3Y72.57%
Revenue Next 5Y52.16%
EBIT growth 1Y-10.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.74%
EBIT Next 3Y33.96%
EBIT Next 5YN/A
FCF growth 1Y-29.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.95%
OCF growth 3YN/A
OCF growth 5YN/A

SCPHARMACEUTICALS INC / SCPH Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SCPHARMACEUTICALS INC (SCPH) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SCPH.


What is the valuation status of SCPHARMACEUTICALS INC (SCPH) stock?

ChartMill assigns a valuation rating of 1 / 10 to SCPHARMACEUTICALS INC (SCPH). This can be considered as Overvalued.


Can you provide the profitability details for SCPHARMACEUTICALS INC?

SCPHARMACEUTICALS INC (SCPH) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for SCPH stock?

The Earnings per Share (EPS) of SCPHARMACEUTICALS INC (SCPH) is expected to grow by 41.66% in the next year.